Incyte Stock - Jefferies nudges target higher after recent gains

Incyte stock gets a modest target lift from Jefferies, which raises its fair-value mark while sticking to a Hold view. On this Thursday, the focus for investors shifts to the chart picture and key technical levels around the recent advance.

Edited by ad hoc news Chart & Technicals Desk. Verified prior to publication on 06/18/2026, 18:35 CET. Details in the imprint.

Incyte (US45337C1027) sees fresh analyst attention this week. Jefferies has raised its price target while reiterating a Hold rating, according to a recent update circulated via MarketScreener. Jefferies update reported by MarketScreener

Jefferies trims discount, stays cautious

Jefferies now sees fair value for Incyte shares at $100, up from $94 previously, and keeps its Hold recommendation unchanged. MarketScreener summary of the Jefferies move That implies only limited upside versus the recent close just below $99.

The updated target comes as Incyte stock has delivered a solid double-digit gain over the past year, supported by a resilient revenue base in oncology and dermatology. The muted rating stance underlines that Jefferies sees the current valuation as broadly fair.

Technical picture on Thursday

On a closing basis, Incyte shares last changed hands at $98.99 on Nasdaq on 06/17/2026, with a modest 0.76% decline on the day. TradingKey quote overview for Incyte Pre-market indications on 06/18/2026 pointed slightly lower again.

At this level, the stock is not far from its recent 52-week highs, leaving the chart in reasonably constructive shape. Against this backdrop, investors are watching whether the shares can consolidate above the mid-$90s band, where trading activity has been dense in recent weeks.

The product engine behind Incyte

Incyte generates most of its revenue from specialty medicines in oncology and inflammation, led by Jakafi (ruxolitinib) for myelofibrosis and polycythemia vera. The company also earns royalty streams and collaboration income from partners on various targeted therapies.

Where the stock trades today

The shares of Incyte (US45337C1027) trade on Nasdaq at $98.99 as of 06/17/2026, 16:00 ET.

Key facts on Incyte stock

• Company: Incyte Corp.
• ISIN: US45337C1027
• WKN: 896133
• Ticker: INCY
• Venue: Nasdaq
• Price (as of 06/17/2026, 16:00 ET): 98.99 USD
• Market cap: 19.78 billion USD (as of 06/17/2026)
• Sector / Industry: Health Care / Biotechnology
• Index membership: Standard & Poor's 500 index
• Next earnings date: not officially scheduled

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.